A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

被引：172
|
作者：
Popat, Rakesh [1 ,2 ]
Plesner, Torben [3 ]
Davies, Faith [4 ]
Cook, Gordon [5 ]
Cook, Mark [6 ]
Elliott, Peter [7 ]
Jacobson, Eric [7 ]
Gumbleton, Todd [1 ]
Oakervee, Heather [1 ]
Cavenagh, Jamie [1 ]
机构：
[1] St Bartholomews Hosp, London, England
[2] UCL Canc Inst, London, England
[3] Vejle Hosp, Vejile, Denmark
[4] Royal Marsden Hosp, Surrey, England
[5] St James Hosp, Leeds LS9 7TF, W Yorkshire, England
[6] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[7] GSK Co, Sirtris, Cambridge, MA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 160卷 / 05期
关键词：
myeloma; clinical trials; renal medicine; APOPTOSIS; PROTEINS;
D O I：
10.1111/bjh.12154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：714 / 717
页数：4
相关论文
共 50 条
  • [41] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [42] A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A. B.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Jia, J.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2017, 102 : 169 - 169
  • [43] Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study
    Richardson, P. G.
    Chanan-Khan, A.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Alsina, M.
    Albitar, M.
    Berman, D.
    Kaplita, S.
    Anderson, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] ANTITUMOR ACTIVITY OF BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS
    Skvortsova, N.
    Pospelova, T.
    Nechunaeva, I.
    Kovalchuk, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 616 - 616
  • [45] ANTITUMOR ACTIVITY OF BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS
    Skvortsova, N.
    Pospelova, T.
    Nechunaeva, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 590 - 590
  • [46] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [47] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [48] A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E16
  • [49] Bortezomib in relapsed or refractory multiple myeloma:: results in a cohort of 39 patients
    Canovas Fernandez, A.
    Alonso Alonso, J. J.
    Barreiro Garcia, J. G.
    Aguirre Errasti, C.
    REVISTA CLINICA ESPANOLA, 2008, 208 (04): : 187 - 192
  • [50] Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
12345